Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Downgraded by Wall Street Zen to Buy

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Sunday.

A number of other research analysts have also recently issued reports on FMS. Citigroup reiterated a “neutral” rating on shares of Fresenius Medical Care AG & Co. KGaA in a report on Friday. Morgan Stanley reissued an “underweight” rating on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Tuesday, January 27th. The Goldman Sachs Group lowered shares of Fresenius Medical Care AG & Co. KGaA from a “buy” rating to a “neutral” rating in a research report on Tuesday, January 20th. Truist Financial set a $28.00 price target on shares of Fresenius Medical Care AG & Co. KGaA in a research report on Monday, January 5th. Finally, Weiss Ratings lowered shares of Fresenius Medical Care AG & Co. KGaA from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, March 13th. Six research analysts have rated the stock with a Hold rating and four have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average target price of $28.00.

Fresenius Medical Care AG & Co. KGaA Stock Up 0.1%

Shares of NYSE FMS opened at $22.77 on Friday. The stock has a market capitalization of $12.72 billion, a P/E ratio of 11.92, a P/E/G ratio of 2.76 and a beta of 0.89. The company has a 50-day moving average price of $23.01 and a 200-day moving average price of $23.72. Fresenius Medical Care AG & Co. KGaA has a 1 year low of $20.94 and a 1 year high of $30.46. The company has a debt-to-equity ratio of 0.40, a current ratio of 1.26 and a quick ratio of 0.92.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) last issued its quarterly earnings data on Saturday, February 14th. The company reported $1.69 earnings per share (EPS) for the quarter. The firm had revenue of $5.95 billion during the quarter. Fresenius Medical Care AG & Co. KGaA had a net margin of 5.03% and a return on equity of 8.73%. On average, equities research analysts forecast that Fresenius Medical Care AG & Co. KGaA will post 2.46 EPS for the current fiscal year.

Institutional Trading of Fresenius Medical Care AG & Co. KGaA

Several hedge funds have recently added to or reduced their stakes in FMS. CIBC Private Wealth Group LLC raised its position in Fresenius Medical Care AG & Co. KGaA by 398.2% in the third quarter. CIBC Private Wealth Group LLC now owns 1,380 shares of the company’s stock worth $36,000 after acquiring an additional 1,103 shares during the period. Arax Advisory Partners raised its position in Fresenius Medical Care AG & Co. KGaA by 121.6% in the fourth quarter. Arax Advisory Partners now owns 1,613 shares of the company’s stock worth $38,000 after acquiring an additional 885 shares during the period. Kestra Advisory Services LLC bought a new stake in Fresenius Medical Care AG & Co. KGaA in the fourth quarter worth about $48,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in Fresenius Medical Care AG & Co. KGaA in the fourth quarter worth about $58,000. Finally, Group One Trading LLC bought a new stake in Fresenius Medical Care AG & Co. KGaA in the third quarter worth about $74,000. Institutional investors own 8.37% of the company’s stock.

About Fresenius Medical Care AG & Co. KGaA

Fresenius Medical Care AG & Co KGaA is the world’s largest integrated provider of products and services for individuals with renal diseases. The company’s primary business activities encompass the operation of dialysis clinics and the manufacture and distribution of dialysis equipment, dialysis machines, dialyzers, consumables and related therapies. Through its global network of clinics, Fresenius Medical Care delivers comprehensive kidney care, including hemodialysis and peritoneal dialysis treatments, patient education and support services.

In its products segment, the company designs and produces dialysis machines, water treatment systems and disposables such as high‐flux dialyzers and bloodlines.